These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37738952)

  • 1. Repurposing SGLT2 inhibitors for autoimmune diseases? YES, WE MAY!
    Certo M; Niven J; Mauro C
    Cell Chem Biol; 2023 Sep; 30(9):1009-1011. PubMed ID: 37738952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Canagliflozin impairs T cell effector function via metabolic suppression in autoimmunity.
    Jenkins BJ; Blagih J; Ponce-Garcia FM; Canavan M; Gudgeon N; Eastham S; Hill D; Hanlon MM; Ma EH; Bishop EL; Rees A; Cronin JG; Jury EC; Dimeloe SK; Veale DJ; Thornton CA; Vousden KH; Finlay DK; Fearon U; Jones GW; Sinclair LV; Vincent EE; Jones N
    Cell Metab; 2023 Jul; 35(7):1132-1146.e9. PubMed ID: 37230079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetes mellitus: Cardiovascular and renal benefits of SGLT2 inhibition: insights from CANVAS.
    Vallon V; Thomson SC
    Nat Rev Nephrol; 2017 Sep; 13(9):517-518. PubMed ID: 28781373
    [No Abstract]   [Full Text] [Related]  

  • 4. Research digest: SGLT2 inhibition in kidney and liver disease.
    Preiss D; Sattar N
    Lancet Diabetes Endocrinol; 2019 Jun; 7(6):427. PubMed ID: 31103176
    [No Abstract]   [Full Text] [Related]  

  • 5. [In patients with type 2 diabetes and diabetic nephropathy with albuminuria, what is the effect of SGLT2 inhibitor canagliflozin on renal and cardiovascular outcomes?].
    Lanthier L; Huard G; Plourde MÉ; Cauchon M
    Rev Med Interne; 2020 Jan; 41(1):67-68. PubMed ID: 31812446
    [No Abstract]   [Full Text] [Related]  

  • 6. Feasibility Study to Assess Canagliflozin Distribution and Sodium-Glucose Co-Transporter 2 Occupancy Using [
    van der Hoek S; Willemsen ATM; Visser T; Heeres A; Mulder DJ; Bokkers RPH; Slart RHJA; Elsinga PH; Heerspink HJL; Stevens J
    Clin Pharmacol Ther; 2023 Jun; 113(6):1295-1303. PubMed ID: 36897753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Canagliflozin regulates metabolic reprogramming in diabetic kidney disease by inducing fasting-like and aestivation-like metabolic patterns.
    Shao M; Chen D; Wang Q; Guo F; Wei F; Zhang W; Gan T; Luo Y; Fan X; Du P; Liu Y; Ma X; Ren G; Song Y; Zhao Y; Qin G
    Diabetologia; 2024 Apr; 67(4):738-754. PubMed ID: 38236410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Model-Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With Canagliflozin.
    Brady JA; Hallow KM
    J Clin Pharmacol; 2018 Mar; 58(3):377-385. PubMed ID: 29144539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: A retrospective cohort study.
    Yuan Z; DeFalco FJ; Ryan PB; Schuemie MJ; Stang PE; Berlin JA; Desai M; Rosenthal N
    Diabetes Obes Metab; 2018 Mar; 20(3):582-589. PubMed ID: 28898514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of sodium glucose co-transporter 2 inhibitors on non-alcoholic fatty liver disease.
    Chrysavgis L; Papatheodoridi AM; Chatzigeorgiou A; Cholongitas E
    J Gastroenterol Hepatol; 2021 Apr; 36(4):893-909. PubMed ID: 33439540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Canagliflozin, an Inhibitor of the Na
    Shim B; Stokum JA; Moyer M; Tsymbalyuk N; Tsymbalyuk O; Keledjian K; Ivanova S; Tosun C; Gerzanich V; Simard JM
    Cells; 2023 Sep; 12(18):. PubMed ID: 37759444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Canagliflozin: A Review in Type 2 Diabetes.
    Deeks ED; Scheen AJ
    Drugs; 2017 Sep; 77(14):1577-1592. PubMed ID: 28836175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of canagliflozin on the overall clinical state including insulin resistance in Japanese patients with type 2 diabetes mellitus.
    Koike Y; Shirabe SI; Maeda H; Yoshimoto A; Arai K; Kumakura A; Hirao K; Terauchi Y
    Diabetes Res Clin Pract; 2019 Mar; 149():140-146. PubMed ID: 30716347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors.
    Wilcox CS
    Hypertension; 2020 Apr; 75(4):894-901. PubMed ID: 32114848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes.
    Whalen K; Miller S; Onge ES
    Clin Ther; 2015 Jun; 37(6):1150-66. PubMed ID: 25891804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanistic evaluation of the effect of sodium-dependent glucose transporter 2 inhibitors on delayed glucose absorption in patients with type 2 diabetes mellitus using a quantitative systems pharmacology model of human systemic glucose dynamics.
    Mori-Anai K; Tashima Y; Nakada T; Nakamaru Y; Takahata T; Saito R
    Biopharm Drug Dispos; 2020 Nov; 41(8-9):352-366. PubMed ID: 33085977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing and Contrasting the Effects of the SGLT Inhibitors Canagliflozin and Empagliflozin on the Progression of Retinopathy.
    Herat LY; Matthews JR; Rakoczy EP; Schlaich MP; Matthews VB
    Front Biosci (Landmark Ed); 2023 Apr; 28(4):83. PubMed ID: 37114550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozin.
    Polidori D; Iijima H; Goda M; Maruyama N; Inagaki N; Crawford PA
    Diabetes Obes Metab; 2018 May; 20(5):1321-1326. PubMed ID: 29341404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SGLT inhibitors on weight and body mass: A meta-analysis of 116 randomized-controlled trials.
    Cheong AJY; Teo YN; Teo YH; Syn NL; Ong HT; Ting AZH; Chia AZQ; Chong EY; Chan MY; Lee CH; Lim AYL; Kong WKF; Wong RCC; Chai P; Sia CH
    Obesity (Silver Spring); 2022 Jan; 30(1):117-128. PubMed ID: 34932882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diabetes and Bone Fragility: SGLT2 Inhibitor Use in the Context of Renal and Cardiovascular Benefits.
    Jackson K; Moseley KF
    Curr Osteoporos Rep; 2020 Oct; 18(5):439-448. PubMed ID: 32710428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.